Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Stroke. 2019 Dec 12;51(2):612–618. doi: 10.1161/STROKEAHA.119.027037

Figure 2.

Figure 2.

Bexarotene treatment increases MDMs erythrophagocytosis, accelerates hematoma clearance, and improves behavioral function after autologous blood injection model of ICH. A, Top: representative histogram shows intensity of fluorescently-labeled erythrocytes in MDMs from vehicle- and bexarotene-treated mice at day 3 after ICH. Bottom: Quantification of percentage of MDMs that are positive for labeled erythrocytes. n = 5/group, *P < 0.05 vs vehicle group by Student’s t test. B, Top: representative coronal sections show visible hematoma in the vehicle- and bexarotene-treated mice at day 3 after blood injection. Bottom: Quantification of hematoma volume. n = 13 for vehicle group and n = 12 for bexarotene group, *P < 0.05 vs vehicle group by Student’s t test. C, Cylinder test results of vehicle- and bexarotene-treated mice at day 3 after blood injection. n = 13 for vehicle group and n = 12 for bexarotene group, *P < 0.05 vs vehicle group by 2-way repeated ANOVA and Bonferroni’s post hoc test. Veh, Vehicle; Bex, bexarotene.